News | July 08, 2022
Evonik launches non-animal-derived collagen platform for medical device applications
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Site Enhances New Modality CRDMO Platform Capacity for Customers
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Company is investing more than €100 million in the expansion of the Halle site
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The AICVD tool can predict the risk of cardiovascular disease.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Subscribe To Our Newsletter & Stay Updated
